Boilerplate being tested for clinical trials agreements

The Canadian Institutes of Health Research (CIHR) is hoping to slash startup times for Phase II and III clinical trials in Canada by introducing a standard template for agreements between sponsors and researchers.

As part of a six-month pilot which started in October, the federal granting council began urging members of Canada's Research-Based Pharmaceutical Companies (Rx&D) and the Association of Canadian Academic Healthcare Organizations to use a model "clinical trial template agreement" in negotiations, rather than waste time and money crafting contracts from scratch (www.cihr-irsc.gc.ca/e/44186.html).

The template boils down the relationship and obligations of all parties and provides a benchmark for negotiating typically sticky issues such as intellectual property rights or liability, says Glenn Brimacombe, president and CEO of the association.

"Now, we have one document that effectively addresses almost all of the issues that are on the table when two parties come together," he explains. "We're hoping this is just another piece in the puzzle that will help attract industry to come to Canada and invest in clinical trials."

The cost of drafting unique agreements poses an unnecessary barrier to trial sponsors at a time when Canada is already hemorrhaging clinical trial investment dollars, says Normand Laberge, vice president of regulatory and scientific affairs for Rx&D.

Canadian clinical trial activity has dropped some 35% in recent years, he explains, while other countries, including Spain, Germany and Japan, have

seen increases in clinical research. "Canada is the most expensive country [in which to conduct trials], one of the slowest to initiate trials and not very efficient in terms of [patient] recruitment."

The consequence of Canada's flagging performance is a loss of \$300 million to \$500 million a year in the country's research portfolio, Laberge

Archer, convenor of the chairs' group of the Association of UK University Hospitals, said in a press release (www.dh.gov.uk/en/MediaCentre/Pressreleases/DH_124576).

About 75% of the content in individually crafted clinical trial agreements is virtually identical, while a further 10% is easy to harmonize, according to an internal

report on 19 company agreements undertaken by Rx&D, Laberge says.

Simplifying the contracting process will "bring us one step closer towards increasing the attractiveness of Canada clinical trial sites as preferred partners internationally for clinical trials, and ultimately continue to bring human, social and economic benefits to all," Brimacombe, CIHR President Dr. Alain Beaudet and Rx&D President Russell Williams argued in a press release (www.cihr-irsc.gc.ca/e/44203.html).

Bolstering clinical trial investment levels in Canada will provide relief to the health care system, as treatment of patients enrolled in trials is covered by sponsors, adds Laberge.

What remains to be seen is whether a single template agreement can truly be one-size-fits-all, says Brimacombe. "We'll have to see how generalizable this is and I'm hoping that's one of the issues that will become clearer as we go through the pilot process."

Participants in the pilot are free to tweak the template but CIHR is asking participants to limit changes to "only what is absolutely necessary" and report back on what items were changed. That data will be used to inform revisions to the template.

The pilot will run from October 2011 to April 2012. — Lauren Vogel, *CMAJ*

© 2011 Thinkstock

Squabbling over clinical trial agreements represents a barrier to investment, according to Canada's Research-Based Pharmaceutical Companies (Rx&D).

estimates. "We have lost our competitive edge."

International peers such as the United Kingdom have been using template agreements for the past decade. The UK's National Institute of Health Research states in guidance on the use of such templates that they have been widely recognized as being "fair, even-handed and acceptable to [all] parties," while "their availability usually avoids the lengthy and potentially costly legal review and negotiation that is often required by the use of individual companies' documents" (www.nihr.ac.uk/files/miCRA%20Guidance.pdf).

Template agreements have also served to level the playing field in clinical trial negotiations for academic and public sector organizations, which often don't have the legal resources to "enter confidently into collaborative arrangements with industry," Dr. Mary